COVID 19 pandemic and lockdown: A double whammy for patients with thalassemia. Unprecedented times for patients with thalassemia

Main Article Content

Shruti Kakkar
Vaneet Anand
Priyanka Dewan
Praveen Sobti


Thalassemia, Lockdown, Optimal management


Download data is not yet available.
Abstract 380 | PDF Downloads 180


1. Singh, P. How COVID-19 is endangering the lives of Thalassemia patients. National Herald. (2020, May 8). Retrieved from

2. Prasad, Narayan, Mansi Bhatt, Sanjay K Agarwal, et al. The Adverse Effect of COVID Pandemic on the Care of Patients With Kidney Diseases in India. Kidney International Reports 2020; 5, Issue 9, 1545 – 1550.

3. Dehshal, M. H., Hosoya, S., Bahremani, et al. COVID-19 and Thalassaemia in Iran. Thalassemia Reports, 2020; 10(1).

4. Eleftheriou, A., Cannon, L., & Angastiniotis, M. Thalassaemia prior and consequent to COVID-19 pandemic. The perspective of Thalassaemia International Federation (TIF). Thalassemia Reports, 2020; 10(1).

5. Panigrahi M, Swain TR, Jena RK, et al. Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha. Indian J Pharmacol 2020; 52:172-8.

6. Dhamija M, Mahajan A, Kalra M, et al. Deferasirox in Indian children with thalassemia major: 3 years experience. Indian J Med Paediatr Oncol. 2013;34(1):16-20. doi:10.4103/0971-5851.113407.

Most read articles by the same author(s)